APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orally Disintegrating Tablet

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Selected research

Market Structure

Global Orally Disintegrating Tablet Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174020360327 December 2025198 pages

Choose your research edition.

Industry ResearchOrally Disintegrating Tablet Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Disintegrating Tablet Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Orally Disintegrating Tablet Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Disintegrating Tablet Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Disintegrating Tablet Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Global Orally Disintegrating Tablet main manufactuers include Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb and Conquer, totally accounting for about 17% of the market. North America is the largest market of glass packaging, holding a share more than 40%. As for the types of products, it can be divided into anti-psychotics drug, anti-epileptics drug and others. As for the applications of products, it is widely used in CNS diseases, gastrointestinal diseases, CVS diseases and others. The most common application is in CNS diseases packaging, with a share about 55%.

This report provides an overview of the global Orally Disintegrating Tablet market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Orally Disintegrating Tablet and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orally Disintegrating Tablet sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Orally Disintegrating Tablet market size, projected growth trends, production technologies, key applications, and end-use industries.

Orally Disintegrating Tablet Segment by Company

Teva

Merck

Mylan

Pfizer

Johnson and Johnson

GSK

Otsuka

Eli Lilly and Company

AstraZeneca

Bristol-Myers Squibb

Conquer

Orally Disintegrating Tablet Segment by Type

Anti-Psychotics Drug

Anti-Epileptics Drug

Others

Orally Disintegrating Tablet Segment by Application

CNS Diseases

Gastrointestinal Diseases

CVS Diseases

Others

Orally Disintegrating Tablet Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Disintegrating Tablet market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Disintegrating Tablet and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Disintegrating Tablet.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Orally Disintegrating Tablet market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Orally Disintegrating Tablet manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Orally Disintegrating Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Orally Disintegrating Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Orally Disintegrating Tablet Industry Trends Table 2. Orally Disintegrating Tablet Industry Drivers Table 3. Orally Disintegrating Tablet Industry Opportunities and Challenges Table 4. Orally Disintegrating Tablet Industry Restraints Table 5. Global Orally Disintegrating Tablet Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Orally Disintegrating Tablet Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Orally Disintegrating Tablet Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Orally Disintegrating Tablet Sales Market Share by Manufacturers Table 9. Global Orally Disintegrating Tablet Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Orally Disintegrating Tablet Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Orally Disintegrating Tablet Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Orally Disintegrating Tablet Manufacturers, Product Type & Application Table 13. Global Orally Disintegrating Tablet Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Orally Disintegrating Tablet by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-Psychotics Drug Table 17. Major Manufacturers of Anti-Epileptics Drug Table 18. Major Manufacturers of Others Table 19. Global Orally Disintegrating Tablet Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 20. Global Orally Disintegrating Tablet Sales by Type (2021-2026) & (M Units) Table 21. Global Orally Disintegrating Tablet Sales by Type (2027-2032) & (M Units) Table 22. Global Orally Disintegrating Tablet Sales Market Share by Type (2021-2026) Table 23. Global Orally Disintegrating Tablet Sales Market Share by Type (2027-2032) Table 24. Global Orally Disintegrating Tablet Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 25. Global Orally Disintegrating Tablet Revenue by Type (2021-2026) & (M Units) Table 26. Global Orally Disintegrating Tablet Revenue by Type (2027-2032) & (M Units) Table 27. Global Orally Disintegrating Tablet Revenue Market Share by Type (2021-2026) Table 28. Global Orally Disintegrating Tablet Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of CNS Diseases Table 30. Major Manufacturers of Gastrointestinal Diseases Table 31. Major Manufacturers of CVS Diseases Table 32. Major Manufacturers of Others Table 33. Global Orally Disintegrating Tablet Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 34. Global Orally Disintegrating Tablet Sales by Application (2021-2026) & (M Units) Table 35. Global Orally Disintegrating Tablet Sales by Application (2027-2032) & (M Units) Table 36. Global Orally Disintegrating Tablet Sales Market Share by Application (2021-2026) Table 37. Global Orally Disintegrating Tablet Sales Market Share by Application (2027-2032) Table 38. Global Orally Disintegrating Tablet Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 39. Global Orally Disintegrating Tablet Revenue by Application (2021-2026) & (M Units) Table 40. Global Orally Disintegrating Tablet Revenue by Application (2027-2032) & (M Units) Table 41. Global Orally Disintegrating Tablet Revenue Market Share by Application (2021-2026) Table 42. Global Orally Disintegrating Tablet Revenue Market Share by Application (2027-2032) Table 43. Global Orally Disintegrating Tablet Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 44. Global Orally Disintegrating Tablet Sales by Region (2021-2026) & (M Units) Table 45. Global Orally Disintegrating Tablet Sales Market Share by Region (2021-2026) Table 46. Global Orally Disintegrating Tablet Sales Forecasted by Region (2027-2032) & (M Units) Table 47. Global Orally Disintegrating Tablet Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 49. North America Orally Disintegrating Tablet Sales by Country (2021-2026) & (M Units) Table 50. North America Orally Disintegrating Tablet Sales by Country (2027-2032) & (M Units) Table 51. Europe Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 52. Europe Orally Disintegrating Tablet Sales by Country (2021-2026) & (M Units) Table 53. Europe Orally Disintegrating Tablet Sales by Country (2027-2032) & (M Units) Table 54. Asia Pacific Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 55. Asia Pacific Orally Disintegrating Tablet Sales by Country (2021-2026) & (M Units) Table 56. Asia Pacific Orally Disintegrating Tablet Sales by Country (2027-2032) & (M Units) Table 57. South America, Middle East and Africa Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 58. South America, Middle East and Africa Orally Disintegrating Tablet Sales by Country (2021-2026) & (M Units) Table 59. South America, Middle East and Africa Orally Disintegrating Tablet Sales by Country (2027-2032) & (M Units) Table 60. Global Orally Disintegrating Tablet Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Orally Disintegrating Tablet Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Orally Disintegrating Tablet Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Orally Disintegrating Tablet Revenue Market Share by Region (2021-2026) Table 64. Global Orally Disintegrating Tablet Revenue Market Share by Region (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Orally Disintegrating Tablet Product Portfolio Table 69. Teva Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck Orally Disintegrating Tablet Product Portfolio Table 74. Merck Recent Development Table 75. Mylan Company Information Table 76. Mylan Business Overview Table 77. Mylan Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Mylan Orally Disintegrating Tablet Product Portfolio Table 79. Mylan Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Orally Disintegrating Tablet Product Portfolio Table 84. Pfizer Recent Development Table 85. Johnson and Johnson Company Information Table 86. Johnson and Johnson Business Overview Table 87. Johnson and Johnson Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Johnson and Johnson Orally Disintegrating Tablet Product Portfolio Table 89. Johnson and Johnson Recent Development Table 90. GSK Company Information Table 91. GSK Business Overview Table 92. GSK Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. GSK Orally Disintegrating Tablet Product Portfolio Table 94. GSK Recent Development Table 95. Otsuka Company Information Table 96. Otsuka Business Overview Table 97. Otsuka Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Otsuka Orally Disintegrating Tablet Product Portfolio Table 99. Otsuka Recent Development Table 100. Eli Lilly and Company Company Information Table 101. Eli Lilly and Company Business Overview Table 102. Eli Lilly and Company Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eli Lilly and Company Orally Disintegrating Tablet Product Portfolio Table 104. Eli Lilly and Company Recent Development Table 105. AstraZeneca Company Information Table 106. AstraZeneca Business Overview Table 107. AstraZeneca Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca Orally Disintegrating Tablet Product Portfolio Table 109. AstraZeneca Recent Development Table 110. Bristol-Myers Squibb Company Information Table 111. Bristol-Myers Squibb Business Overview Table 112. Bristol-Myers Squibb Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Bristol-Myers Squibb Orally Disintegrating Tablet Product Portfolio Table 114. Bristol-Myers Squibb Recent Development Table 115. Conquer Company Information Table 116. Conquer Business Overview Table 117. Conquer Orally Disintegrating Tablet Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Conquer Orally Disintegrating Tablet Product Portfolio Table 119. Conquer Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Orally Disintegrating Tablet Distributors List Table 123. Orally Disintegrating Tablet Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Orally Disintegrating Tablet Product Image Figure 2. Global Orally Disintegrating Tablet Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Disintegrating Tablet Market Size (2021-2032) & (US$ Million) Figure 4. Global Orally Disintegrating Tablet Sales (2021-2032) & (M Units) Figure 5. Global Orally Disintegrating Tablet Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Orally Disintegrating Tablet Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-Psychotics Drug Image Figure 9. Anti-Epileptics Drug Image Figure 10. Others Image Figure 11. Global Orally Disintegrating Tablet Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 12. Global Orally Disintegrating Tablet Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Orally Disintegrating Tablet Sales Market Share by Type (2021-2032) Figure 14. Global Orally Disintegrating Tablet Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 15. Global Orally Disintegrating Tablet Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Orally Disintegrating Tablet Revenue Market Share by Type (2021-2032) Figure 17. CNS Diseases Image Figure 18. Gastrointestinal Diseases Image Figure 19. CVS Diseases Image Figure 20. Others Image Figure 21. Global Orally Disintegrating Tablet Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 22. Global Orally Disintegrating Tablet Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Orally Disintegrating Tablet Sales Market Share by Application (2021-2032) Figure 24. Global Orally Disintegrating Tablet Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 25. Global Orally Disintegrating Tablet Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Orally Disintegrating Tablet Revenue Market Share by Application (2021-2032) Figure 27. North America Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 28. North America Orally Disintegrating Tablet Sales Market Share by Country (2021-2032) Figure 29. U.S. Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 30. Canada Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 31. Mexico Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 32. Europe Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 33. Europe Orally Disintegrating Tablet Sales Market Share by Country (2021-2032) Figure 34. Germany Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 35. France Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 36. U.K. Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 37. Italy Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 38. Netherlands Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 39. Asia Pacific Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 40. Asia Pacific Orally Disintegrating Tablet Sales Market Share by Country (2021-2032) Figure 41. China Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 42. Japan Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 43. South Korea Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 44. Southeast Asia Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 45. India Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 46. Australia Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 47. South America, Middle East and Africa Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 48. South America, Middle East and Africa Orally Disintegrating Tablet Sales Market Share by Country (2021-2032) Figure 49. Brazil Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 50. South Africa Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 51. Saudi Arabia Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 52. Turkey Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 53. Argentina Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 54. UAE Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 55. Egypt Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 56. Chile Orally Disintegrating Tablet Sales and Growth Rate (2021-2032) & (M Units) Figure 57. Global Orally Disintegrating Tablet Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Orally Disintegrating Tablet Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Orally Disintegrating Tablet Revenue (2021-2032) & (US$ Million) Figure 60. North America Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Orally Disintegrating Tablet Revenue (2021-2032) & (US$ Million) Figure 62. Europe Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Orally Disintegrating Tablet Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Orally Disintegrating Tablet Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Orally Disintegrating Tablet Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Orally Disintegrating Tablet Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-Psychotics Drug
  • Anti-Epileptics Drug
  • Others
Applications
  • CNS Diseases
  • Gastrointestinal Diseases
  • CVS Diseases
  • Others
Companies covered
  • Teva
  • Merck
  • Mylan
  • Pfizer
  • Johnson and Johnson
  • GSK
  • Otsuka
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb
  • Conquer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orally Disintegrating Tablet Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orally Disintegrating Tablet Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Orally Disintegrating Tablet Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Orally Disintegrating Tablet Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Orally Disintegrating Tablet Market Dynamics
  1. 2.1 Orally Disintegrating Tablet Industry Trends
  2. 2.2 Orally Disintegrating Tablet Industry Drivers
  3. 2.3 Orally Disintegrating Tablet Industry Opportunities and Challenges
  4. 2.4 Orally Disintegrating Tablet Industry Restraints
3 Orally Disintegrating Tablet Market by Manufacturers
  1. 3.1 Global Orally Disintegrating Tablet Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Orally Disintegrating Tablet Sales by Manufacturers (2021-2026)
  3. 3.3 Global Orally Disintegrating Tablet Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Orally Disintegrating Tablet Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Orally Disintegrating Tablet Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Orally Disintegrating Tablet Manufacturers, Product Type & Application
  7. 3.7 Global Orally Disintegrating Tablet Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Orally Disintegrating Tablet Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Orally Disintegrating Tablet Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Orally Disintegrating Tablet Tier 1, Tier 2, and Tier 3
4 Orally Disintegrating Tablet Market by Type
  1. 4.1 Orally Disintegrating Tablet Type Introduction
  2. 4.1.1 Anti-Psychotics Drug
  3. 4.1.2 Anti-Epileptics Drug
  4. 4.1.3 Others
  5. 4.2 Global Orally Disintegrating Tablet Sales by Type
  6. 4.2.1 Global Orally Disintegrating Tablet Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Orally Disintegrating Tablet Sales by Type (2021-2032)
  8. 4.2.3 Global Orally Disintegrating Tablet Sales Market Share by Type (2021-2032)
  9. 4.3 Global Orally Disintegrating Tablet Revenue by Type
  10. 4.3.1 Global Orally Disintegrating Tablet Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Orally Disintegrating Tablet Revenue by Type (2021-2032)
  12. 4.3.3 Global Orally Disintegrating Tablet Revenue Market Share by Type (2021-2032)
5 Orally Disintegrating Tablet Market by Application
  1. 5.1 Orally Disintegrating Tablet Application Introduction
  2. 5.1.1 CNS Diseases
  3. 5.1.2 Gastrointestinal Diseases
  4. 5.1.3 CVS Diseases
  5. 5.1.4 Others
  6. 5.2 Global Orally Disintegrating Tablet Sales by Application
  7. 5.2.1 Global Orally Disintegrating Tablet Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Orally Disintegrating Tablet Sales by Application (2021-2032)
  9. 5.2.3 Global Orally Disintegrating Tablet Sales Market Share by Application (2021-2032)
  10. 5.3 Global Orally Disintegrating Tablet Revenue by Application
  11. 5.3.1 Global Orally Disintegrating Tablet Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Orally Disintegrating Tablet Revenue by Application (2021-2032)
  13. 5.3.3 Global Orally Disintegrating Tablet Revenue Market Share by Application (2021-2032)
6 Global Orally Disintegrating Tablet Sales by Region
  1. 6.1 Global Orally Disintegrating Tablet Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orally Disintegrating Tablet Sales by Region (2021-2032)
  3. 6.2.1 Global Orally Disintegrating Tablet Sales by Region (2021-2026)
  4. 6.2.2 Global Orally Disintegrating Tablet Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Orally Disintegrating Tablet Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Orally Disintegrating Tablet Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Orally Disintegrating Tablet Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Orally Disintegrating Tablet Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Orally Disintegrating Tablet Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Orally Disintegrating Tablet Revenue by Region
  1. 7.1 Global Orally Disintegrating Tablet Revenue by Region
  2. 7.1.1 Global Orally Disintegrating Tablet Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Orally Disintegrating Tablet Revenue by Region (2021-2026)
  4. 7.1.3 Global Orally Disintegrating Tablet Revenue by Region (2027-2032)
  5. 7.1.4 Global Orally Disintegrating Tablet Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Orally Disintegrating Tablet Revenue (2021-2032)
  8. 7.2.2 North America Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Orally Disintegrating Tablet Revenue (2021-2032)
  11. 7.3.2 Europe Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Orally Disintegrating Tablet Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Orally Disintegrating Tablet Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Orally Disintegrating Tablet Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Orally Disintegrating Tablet Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Orally Disintegrating Tablet Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Orally Disintegrating Tablet Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Orally Disintegrating Tablet Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Johnson and Johnson
  26. 8.5.1 Johnson and Johnson Company Information
  27. 8.5.2 Johnson and Johnson Business Overview
  28. 8.5.3 Johnson and Johnson Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson and Johnson Orally Disintegrating Tablet Product Portfolio
  30. 8.5.5 Johnson and Johnson Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Orally Disintegrating Tablet Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 Otsuka
  38. 8.7.1 Otsuka Company Information
  39. 8.7.2 Otsuka Business Overview
  40. 8.7.3 Otsuka Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Otsuka Orally Disintegrating Tablet Product Portfolio
  42. 8.7.5 Otsuka Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Orally Disintegrating Tablet Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Orally Disintegrating Tablet Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Orally Disintegrating Tablet Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Conquer
  62. 8.11.1 Conquer Company Information
  63. 8.11.2 Conquer Business Overview
  64. 8.11.3 Conquer Orally Disintegrating Tablet Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Conquer Orally Disintegrating Tablet Product Portfolio
  66. 8.11.5 Conquer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Orally Disintegrating Tablet Value Chain Analysis
  2. 9.1.1 Orally Disintegrating Tablet Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Orally Disintegrating Tablet Production Mode & Process
  6. 9.2 Orally Disintegrating Tablet Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Orally Disintegrating Tablet Distributors
  9. 9.2.3 Orally Disintegrating Tablet Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst